News Feature

Filter By:

Article Type
  • While dealmaking in oncology continued to feature immunotherapies—particularly multi-targeted agents—there was also diversification, with prominent deals for precision medicine and novel platform technologies.

    • Sarah Hardison
    News Feature
  • M&A activity in the biopharma industry continued to boom last year, with more than 200 deals collectively worth over $200 billion.

    • Biopharma Dealmakers
    • DealForma
    News Feature
  • Applications are now open for The Spinoff Prize — a new award for early stage university spinoff companies from around the world!

    • Raveena Bhambra
    News Feature
  • The complement pathway’s intricate network of proteins, which have a key role in the innate immune system, are attracting dealmakers’ attention as targets for a variety of inflammatory diseases.

    • Biopharma Dealmakers
    News Feature
  • 2019 has seen a boom in high-value M&A and licensing deals, with oncology and rare diseases as prominent themes.

    • Biopharma Dealmakers
    News Feature
  • Even for the most seasoned dealmakers, successful deals require coordination, planning and collaboration throughout the process. This article explores the people and stages required to close a successful licensing and collaboration deal from the perspective of dealmakers at Eli Lilly.

    • Jennifer M. A. Laird
    • Katie Hewitt
    News Feature
  • Immuno-oncology continues to be a highly active area for dealmaking as leading companies seek to expand the treatable patient population for checkpoint inhibitors in indications such as non-small-cell lung cancer and achieve initial success in indications such as pancreatic cancer.

    • Nick Taylor
    News Feature
  • As a key component in deal negotiations, a term sheet must be planned carefully and set out optimally for an asset. Lubor Gaal from Locust Walk discusses how licencors can negotiate the best terms for their biopharma assets.

    • Lubor Gaal
    News Feature
  • July and August saw a handful of high-value deals during what is usually a quiet time for dealmaking. In the most valuable deal in this period and also one of the largest this year, Amgen paid Celgene $13.4 billion for Otezla, an oral psoriasis therapy.

    • Raveena Bhambra
    News Feature
  • Established monoclonal antibody therapies have had unprecedented levels of commercial success, but the market is now changing owing to patent expirations and the rise of cancer immunotherapies

    • Biopharma Dealmakers
    News Feature
  • Opportunities are rising for small biotech companies but so are challenges in scaling. In the first of our Thought Leader series, Marc Funk, CEO of Lonza, talks to us about the new business models and technology the company is developing to help companies remain independent.

    • Biopharma Dealmakers
    News Feature
  • Plentiful acquisitions, increased financing and pioneering digital health approvals all shaped the medtech industry in 2018. With nontraditional players such as Apple and Google engaging in the field, the industry looks set to evolve further.

    • Amanda Micklus
    • Maureen Riordan
    News Feature
  • Over the past year, the biopharma industry has witnessed some landmark approvals, high-value merger and acquisition deals and phenomenal venture funding in the US. In this feature, we chart the key trends in biopharma dealmaking since June 2018.

    • DealForma
    • Biopharma Dealmakers
    News Feature
  • In the largest deal of the month and the second largest M&A of the year, AbbVie announced its $63 billion acquisition of Allergan.

    • Raveena Bhambra
    News Feature
  • The validation of novel therapeutic modalities such as gene therapy is supporting deal activity and investment in the development of drugs for central nervous system disorders, particularly for neurodegenerative diseases.

    • Cormac Sheridan
    News Feature
  • A handful of notable acquisitions took place in May, bringing in assets and platforms for major biopharma companies.

    • Raveena Bhambra
    News Feature
  • We bring together recent therapy and technology features, based upon some of March's largest biopharma deals.

    • Raveena Bhambra
    News Feature